Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review.
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK.
The role of genetic sequencing in the diagnostic workup for chronic immune thrombocytopenia.
Patient survey in immune thrombocytopenia (ITP): Identifying unmet needs related to treatment and disease control in patients living in the United States.
Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit.
Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs.
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial.
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment.
Rare disease genomic testing in the UK and Ireland: promoting timely and equitable access.
Evaluating the clinical validity of genes related to hemostasis and thrombosis using the Clinical Genome Resource gene curation framework.
Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis.
Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-centre review.
Could machine learning revolutionize how we treat immune thrombocytopenia?
T Cell Clonality in Paediatric Immune Thrombocytopenia
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
The role of CD8+ T-cell clones in immune thrombocytopenia.
The role of CD8+ T cell clones in immune thrombocytopenia
Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study.
Romiplostim use in pregnant women with immune thrombocytopenia.
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
The role of genetics in refractory immune thrombocytopenia.
P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
2023cited by 0position: contributor